Please login to the form below

Not currently logged in
Email:
Password:

IRX Therapeutics appoints Luba Greenwood to its board

She recently served as venture partner at Colt Ventures

Clinical-stage company IRX Therapeutics has appointed Luba Greenwood to its board of directors.

Her career has seen her gain significant pharmaceutical and biotechnology industry expertise, including building technology companies and providing strategic counsel to corporations.

Mark Leuchtenberger, president and chief executive officer, IRX Therapeutics, said: “Luba is a proven and respected leader in the life science sector.

“She has excelled as an investor, business development professional, lawyer and corporate strategist.”

Her career has spanned leadership roles in venture investing, business development, mergers and acquisitions, law, consulting and operations.

Greenwood most recently served as venture partner at Colt Ventures, and led business development strategy for Pronutria.

Prior to that, she served as senior mergers and acquisitions counsel at Pfizer.

She said: “I look forward to working with the management team as they explore the potential to reduce immune suppression in the tumour microenvironment with IRX-2.”

6th December 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics